Literature DB >> 10760358

CP-101,606, an NR2B subunit selective NMDA receptor antagonist, inhibits NMDA and injury induced c-fos expression and cortical spreading depression in rodents.

F S Menniti1, M J Pagnozzi, P Butler, B L Chenard, S S Jaw-Tsai, W Frost White.   

Abstract

(1S, 2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol (CP-101,606) is a noncompetitive antagonist of N-methyl-D-aspartate (NMDA) receptors containing the NR2B subunit. This compound was used to investigate the role of NR2B containing receptors in three responses to NMDA receptor activation in vivo. In mouse, CP-101,606 completely inhibited increases in fos-like immunoreactivity in dentate gyrus caused by a subconvulsant intraperitoneal dose of NMDA. In rat, the compound completely blocked cortical c-fos mRNA induction following focal injury in parietal cortex and the initiation and propagation of electrically induced cortical spreading depression. Inhibition of these responses by CP-101,606 indicates that c-fos induction and cortical spreading depression are dependent on activation of NMDA receptors containing the NR2B subunit. Since NMDA receptor dependent c-fos induction and cortical spreading depression may contribute to neuron loss after focal CNS injury, inhibition of these responses by CP-101,606 may contribute to the neuroprotective efficacy of the compound.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10760358     DOI: 10.1016/s0028-3908(99)00211-7

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  12 in total

Review 1.  Long-Term Consequences of Traumatic Brain Injury: Current Status of Potential Mechanisms of Injury and Neurological Outcomes.

Authors:  Helen M Bramlett; W Dalton Dietrich
Journal:  J Neurotrauma       Date:  2014-12-19       Impact factor: 5.269

Review 2.  Chaos and commotion in the wake of cortical spreading depression and spreading depolarizations.

Authors:  Daniela Pietrobon; Michael A Moskowitz
Journal:  Nat Rev Neurosci       Date:  2014-06       Impact factor: 34.870

3.  The Bioactive Protein-Ligand Conformation of GluN2C-Selective Positive Allosteric Modulators Bound to the NMDA Receptor.

Authors:  Thomas M Kaiser; Steven A Kell; Hirofumi Kusumoto; Gil Shaulsky; Subhrajit Bhattacharya; Matthew P Epplin; Katie L Strong; Eric J Miller; Bryan D Cox; David S Menaldino; Dennis C Liotta; Stephen F Traynelis; Pieter B Burger
Journal:  Mol Pharmacol       Date:  2017-12-14       Impact factor: 4.436

4.  Brain-specific Phgdh deletion reveals a pivotal role for L-serine biosynthesis in controlling the level of D-serine, an N-methyl-D-aspartate receptor co-agonist, in adult brain.

Authors:  Jung Hoon Yang; Akira Wada; Kazuyuki Yoshida; Yurika Miyoshi; Tomoko Sayano; Kayoko Esaki; Masami O Kinoshita; Shozo Tomonaga; Norihiro Azuma; Masahiko Watanabe; Kenji Hamase; Kiyoshi Zaitsu; Takeo Machida; Albee Messing; Shigeyoshi Itohara; Yoshio Hirabayashi; Shigeki Furuya
Journal:  J Biol Chem       Date:  2010-10-21       Impact factor: 5.157

5.  Lack of efficacy of NMDA receptor-NR2B selective antagonists in the R6/2 model of Huntington disease.

Authors:  Sara J Tallaksen-Greene; Anita Janiszewska; Kasha Benton; Lech Ruprecht; Roger L Albin
Journal:  Exp Neurol       Date:  2010-07-24       Impact factor: 5.330

6.  Systematic review of the pharmacological agents that have been tested against spreading depolarizations.

Authors:  Anna Klass; Renan Sánchez-Porras; Edgar Santos
Journal:  J Cereb Blood Flow Metab       Date:  2018-04-20       Impact factor: 6.200

7.  Effects of NMDA receptor antagonists with different subtype selectivities on retinal spreading depression.

Authors:  Minyan Wang; Paul L Chazot; Sura Ali; Stevens F Duckett; Tihomir P Obrenovitch
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

8.  Reduced NR2A expression and prolonged decay of NMDA receptor-mediated synaptic current in rat vagal motoneurons following axotomy.

Authors:  Junichi Nabekura; Tsuyoshi Ueno; Shutaro Katsurabayashi; Akiko Furuta; Norio Akaike; Masayoshi Okada
Journal:  J Physiol       Date:  2002-03-15       Impact factor: 5.182

Review 9.  Pharmacology of traumatic brain injury: where is the "golden bullet"?

Authors:  Kathryn Beauchamp; Haitham Mutlak; Wade R Smith; Esther Shohami; Philip F Stahel
Journal:  Mol Med       Date:  2008-08-18       Impact factor: 6.354

10.  Treatment with the snail peptide CGX-1007 reduces DNA damage and alters gene expression of c-fos and bcl-2 following focal ischemic brain injury in rats.

Authors:  A J Williams; G Ling; R Berti; J R Moffett; C Yao; X M Lu; J R Dave; F C Tortella
Journal:  Exp Brain Res       Date:  2003-08-29       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.